Aimée Dallob

1.8k total citations
27 papers, 1.2k citations indexed

About

Aimée Dallob is a scholar working on Pharmacology, Molecular Biology and Cellular and Molecular Neuroscience. According to data from OpenAlex, Aimée Dallob has authored 27 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Pharmacology, 6 papers in Molecular Biology and 5 papers in Cellular and Molecular Neuroscience. Recurrent topics in Aimée Dallob's work include Inflammatory mediators and NSAID effects (10 papers), Antiplatelet Therapy and Cardiovascular Diseases (4 papers) and Eicosanoids and Hypertension Pharmacology (4 papers). Aimée Dallob is often cited by papers focused on Inflammatory mediators and NSAID effects (10 papers), Antiplatelet Therapy and Cardiovascular Diseases (4 papers) and Eicosanoids and Hypertension Pharmacology (4 papers). Aimée Dallob collaborates with scholars based in United States, United Kingdom and Belgium. Aimée Dallob's co-authors include Stacia Kargman, Barry J. Gertz, Ian W. Rodger, Elliot Ehrich, Chi‐Chung Chan, Christine Brideau, Eitan Friedman, Jules I. Schwartz, Wesley Tanaka and David L. Ebel and has published in prestigious journals such as Journal of Biological Chemistry, Gastroenterology and The Journal of Clinical Endocrinology & Metabolism.

In The Last Decade

Aimée Dallob

27 papers receiving 1.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Aimée Dallob United States	18	648	210	202	192	174	27	1.2k
Robert J. Workman United States	19	508 0.8×	377 1.8×	476 2.4×	109 0.6×	354 2.0×	38	1.8k
A.I. Ally Canada	18	203 0.3×	307 1.5×	185 0.9×	130 0.7×	145 0.8×	43	980
J M Sneddon United Kingdom	14	175 0.3×	345 1.6×	331 1.6×	285 1.5×	203 1.2×	30	1.2k
Michael Haurand Germany	14	341 0.5×	320 1.5×	510 2.5×	217 1.1×	33 0.2×	20	1.4k
Peter Nguyen United States	16	567 0.9×	366 1.7×	156 0.8×	323 1.7×	60 0.3×	36	1.3k
Donald W. DuCharme United States	17	256 0.4×	982 4.7×	325 1.6×	208 1.1×	409 2.4×	31	1.9k
P. R. Sundaresan United States	24	404 0.6×	562 2.7×	384 1.9×	136 0.7×	121 0.7×	72	1.9k
Hiroshi Shinyama Japan	12	337 0.5×	402 1.9×	814 4.0×	65 0.3×	227 1.3×	38	2.3k
Mao‐Hsiung Yen Taiwan	20	125 0.2×	476 2.3×	371 1.8×	88 0.5×	299 1.7×	31	1.3k
Wen‐Liang Song United States	24	348 0.5×	325 1.5×	545 2.7×	69 0.4×	261 1.5×	37	1.9k

Countries citing papers authored by Aimée Dallob

Since Specialization

Citations

This map shows the geographic impact of Aimée Dallob's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Aimée Dallob with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Aimée Dallob more than expected).

Fields of papers citing papers by Aimée Dallob

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Aimée Dallob. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Aimée Dallob. The network helps show where Aimée Dallob may publish in the future.

Co-authorship network of co-authors of Aimée Dallob

This figure shows the co-authorship network connecting the top 25 collaborators of Aimée Dallob. A scholar is included among the top collaborators of Aimée Dallob based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Aimée Dallob. Aimée Dallob is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Williams, Jonathan H., Gordon Wilcock, Jeffrey L. Seeburger, et al.. (2011). Non-linear relationships of cerebrospinal fluid biomarker levels with cognitive function: an observational study. Alzheimer s Research & Therapy. 3(1). 5–5. 19 indexed citations

Dallob, Aimée, Wen‐Lin Luo, Amy O. Johnson‐Levonas, et al.. (2011). The effects of laropiprant, a selective prostaglandin D₂receptor 1 antagonist, on the antiplatelet activity of clopidogrel or aspirin. Platelets. 22(7). 495–503. 8 indexed citations

Lai, Eseng, Jules I. Schwartz, Aimée Dallob, et al.. (2010). Effects of extended release niacin/laropiprant, laropiprant, extended release niacin and placebo on platelet aggregation and bleeding time in healthy subjects. Platelets. 21(3). 191–198. 14 indexed citations

Schwartz, Jules I., Aimée Dallob, Patrick Larson, et al.. (2008). Comparative Inhibitory Activity of Etoricoxib, Celecoxib, and Diclofenac on COX‐2 Versus COX‐1 in Healthy Subjects. The Journal of Clinical Pharmacology. 48(6). 745–754. 35 indexed citations

Seeburger, Jeffrey L., Daniel Holder, Abderrahim Oulhaj, et al.. (2008). P3‐092: Prediction of short‐term and long‐term cognitive decline in moderate Alzheimer's disease patients in the Oxford project to investigate memory and aging (optima) cohort using CSF biomarkers. Alzheimer s & Dementia. 4(4S_Part_16). 1 indexed citations

Dallob, Aimée, Christopher J. Hawkey, Howard Greenberg, et al.. (2003). Characterization of Etoricoxib, a Novel, Selective COX-2 Inhibitor. The Journal of Clinical Pharmacology. 43(6). 573–585. 8 indexed citations

Calder, Nicole, Aimée Dallob, Peggy Wong, et al.. (2000). Evidence that the COX-2 specific inhibitor rofecoxib at 50 mg spares gastric mucosal prostaglandin synthesis in human. Gastroenterology. 118(4). A253–A253. 7 indexed citations

Hecken, Anne Van, Jules I. Schwartz, Marleen Depré, et al.. (2000). Comparative Inhibitory Activity of Rofecoxib, Meloxicam, Diclofenac, Ibuprofen, and Naproxen on COX‐2 versus COX‐1 in Healthy Volunteers. The Journal of Clinical Pharmacology. 40(10). 1109–1120. 285 indexed citations

Dallob, Aimée, Inge De Lepeleire, Anne Van Hecken, et al.. (1999). Ex vivo assays demonstrate potency and selectivity of the COX-2 inhibitor DFP after single dose administration. Inflammation Research. 48(S2). 130–131. 6 indexed citations

10.

Schwartz, Jules I., Wesley Tanaka, David L. Ebel, et al.. (1997). MK-386, an Inhibitor of 5α-Reductase Type 1, Reduces Dihydrotestosterone Concentrations in Serum and Sebum without Affecting Dihydrotestosterone Concentrations in Semen¹. The Journal of Clinical Endocrinology & Metabolism. 82(5). 1373–1377. 30 indexed citations

11.

Schwartz, Jules I., Wesley Tanaka, David L. Ebel, et al.. (1997). MK-386, an Inhibitor of 5 alpha-Reductase Type 1, Reduces Dihydrotestosterone Concentrations in Serum and Sebum Without Affecting Dihydrotestosterone Concentrations in Semen. Obstetrical & Gynecological Survey. 52(9). 555–557. 9 indexed citations

12.

Brideau, Christine, Stacia Kargman, Aimée Dallob, et al.. (1996). A human whole blood assay for clinical evaluation of biochemical efficacy of cyclooxygenase inhibitors. Inflammation Research. 45(2). 68–74. 241 indexed citations

13.

Friedman, Beth S., Anne Van Hecken, Inge De Lepeleire, et al.. (1994). Pharmacokinetics and pharmacodynamics of multiple oral doses of MK-0591, a 5-lipoxygenase—activating protein inhibitor. Clinical Pharmacology & Therapeutics. 56(1). 22–30. 16 indexed citations

14.

Dallob, Aimée. (1994). The effect of finasteride, a 5 alpha-reductase inhibitor, on scalp skin testosterone and dihydrotestosterone concentrations in patients with male pattern baldness. The Journal of Clinical Endocrinology & Metabolism. 79(3). 703–706. 70 indexed citations

15.

Lau, Cheuk K., Patrice C. Bélanger, John Scheigetz, et al.. (1989). Synthesis and structure-activity relationships of a novel class of 5-lipoxygenase inhibitors. 2-(Phenylmethyl)-4-hydroxy-3,5-dialkylbenzofurans: the development of L-656,224. Journal of Medicinal Chemistry. 32(6). 1190–1197. 18 indexed citations

16.

Dallob, Aimée, Yvan Guindon, & Marvin M. Goldenberg. (1987). Pharmacological evidence for a role of lipoxygenase products in platelet-activating factor (PAF)-induced hyperalgesia. Biochemical Pharmacology. 36(19). 3201–3204. 25 indexed citations

17.

Guindon, Yvan, Yves Girard, Alan L. Maycock, et al.. (1987). L-651,392: a novel, potent and selective 5-lipoxygenase inhibitor.. PubMed. 17A. 554–7. 24 indexed citations

18.

Opas, Evan E., et al.. (1987). Pharmacological modulation of eicosanoid levels and hyperalgesia in yeast-induced inflammation. Biochemical Pharmacology. 36(4). 547–551. 23 indexed citations

19.

Friedman, Eitan & Aimée Dallob. (1979). Enhanced serotonin receptor activity after chronic treatment with imipramine or amitriptyline.. Munich Personal RePEc Archive (Ludwig Maximilian University of Munich). 3(2). 89–92. 54 indexed citations

20.

Friedman, Eitan, et al.. (1979). The effect of long-term lithium treatment on reserpine-induced supersensitivity in dopaminergic and serotonergic transmission. Life Sciences. 25(14). 1263–1266. 21 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact